Leading French cancer research centre combining clinical oncology with fundamental epigenetics, genomics, and cell biology across 83 H2020 projects.
Institut Curie is one of Europe's premier cancer research and treatment centres, combining fundamental research in cell biology, genetics, and epigenetics with clinical oncology. Their H2020 portfolio reveals deep expertise in understanding cancer at the molecular level — from chromatin dynamics and X-chromosome inactivation to breast cancer risk modeling and pediatric tumors. They also run major doctoral training programs and contribute to shared research infrastructures like bioimaging platforms, making them both a knowledge producer and a talent pipeline for European life sciences.
Core theme across projects including UM Cure 2020 (uveal melanoma therapy), BRIDGES (breast cancer genetic risk), ITCC-P4 (pediatric cancer), FiBRO (rectal cancer), and INTEGRISTEM (mammary tumorigenesis).
Deep specialization shown through ChromADICT (histone chaperones), CHROMATIX (X-chromosome inactivation), EPOCH28 (epigenetic profiling), and Drug-Seq (genomic targets of drugs).
Major investment in MSCA programmes (18 fellowships/networks) including their flagship IC-3i-PhD program training interdisciplinary cancer researchers.
Growing capability evidenced by PanCanRisk (bioinformatics for cancer susceptibility), Drug-Seq (high-throughput sequencing), and increasing keyword frequency in recent projects.
Projects like BIOPOL (mechanochemical mechanisms in polarized cells), DivIDe (cell division from oocyte to synthetic biology), and membrane-ezrin-actin interactions.
SmartCells (lab-on-chips for cell control) and MIMIC (organs-on-chips for drug screening) signal growing interest in micro-engineering applied to biology.
In the early H2020 period (2015–2018), Institut Curie focused heavily on fundamental cancer biology — breast cancer genetic susceptibility (BRIDGES), epigenetic profiling of chemotherapy (EPOCH28), and systems biology approaches, alongside gender equality initiatives (LIBRA). From 2019 onward, their portfolio shifted noticeably toward genomics, bioinformatics, and translational research, with increased emphasis on chromatin biology, microbiome studies, and training the next generation of computational biologists. This evolution reflects a move from observing cancer mechanisms to building the data-driven and computational tools needed to act on that knowledge clinically.
Institut Curie is investing heavily in bioinformatics capacity and interdisciplinary PhD training, positioning itself as a hub where computational biology meets clinical oncology.
Institut Curie operates as a true consortium leader — coordinating 38 out of 83 projects (46%), which is exceptionally high for a research centre. They maintain a vast network of 473 unique partners across 37 countries, indicating they function as a major European hub rather than working with a small circle of repeat collaborators. Their strong MSCA portfolio (both individual fellowships and training networks) means they also attract and host international researchers, making them a gateway into French and European life science networks.
With 473 unique consortium partners spanning 37 countries, Institut Curie has one of the broadest collaboration networks in European cancer research. Their reach is truly pan-European with significant connections beyond EU borders, reflecting their status as a globally recognized institution.
Institut Curie combines what few institutions can: a world-class research hospital treating cancer patients daily with fundamental research labs producing breakthrough science in epigenetics, cell biology, and genomics. This means their research is directly informed by clinical reality — projects move from bench to bedside within the same institution. For consortium builders, partnering with Curie brings both scientific credibility and access to clinical validation that pure research institutes cannot offer.
